Skip to main content
Top
Published in: Trials 1/2014

Open Access 01-12-2014 | Commentary

Five questions that need answering when considering the design of clinical trials

Authors: Timothy Clark, Hugh Davies, Ulrich Mansmann

Published in: Trials | Issue 1/2014

Login to get access

Abstract

Evidence suggests that research protocols often lack important information on study design, which hinders external review. The study protocol should provide an adequate explanation for why the proposed study methodology is appropriate for the question posed, why the study design is likely to answer the research question, and why it is the best approach. It is especially important that researchers explain why the treatment difference sought is worthwhile to patients, and they should reference consultations with the public and patient groups and existing literature. Moreover, the study design should be underpinned by a systematic review of the existing evidence, which should be included in the research protocol. The Health Research Authority in collaboration with partners has published guidance entitled ‘Specific questions that need answering when considering the design of clinical trials’. The guidance will help those designing research and those reviewing it to address key issues.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Clark T, Ursula Berger U, Mansmann U: Sample size determinations in original study protocols for randomised clinical trials submitted to UK research ethics committees: review. BMJ. 2013, 346: f1135-10.1136/bmj.f1135.CrossRefPubMedPubMedCentral Clark T, Ursula Berger U, Mansmann U: Sample size determinations in original study protocols for randomised clinical trials submitted to UK research ethics committees: review. BMJ. 2013, 346: f1135-10.1136/bmj.f1135.CrossRefPubMedPubMedCentral
3.
go back to reference Clark T: Sample Size Calculations in Clinical Trials of Investigational Medicinal Products: An Analysis of Ongoing Practice. 2013, Der Andere Verlag Clark T: Sample Size Calculations in Clinical Trials of Investigational Medicinal Products: An Analysis of Ongoing Practice. 2013, Der Andere Verlag
5.
go back to reference Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials. 1998, Springer, 3CrossRef Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials. 1998, Springer, 3CrossRef
6.
go back to reference Chalmers I, Glasziou P, Godlee F: All trials must be registered and the results published. BMJ. 2013, 346: f105-10.1136/bmj.f105.CrossRefPubMed Chalmers I, Glasziou P, Godlee F: All trials must be registered and the results published. BMJ. 2013, 346: f105-10.1136/bmj.f105.CrossRefPubMed
7.
go back to reference Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D: SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013, 346: e7586-10.1136/bmj.e7586.CrossRefPubMedPubMedCentral Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D: SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013, 346: e7586-10.1136/bmj.e7586.CrossRefPubMedPubMedCentral
9.
go back to reference Clarke M, Hopewell S, Chalmers I: Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting. Lancet. 2010, 376: 20-21. 10.1016/S0140-6736(10)61045-8.CrossRefPubMed Clarke M, Hopewell S, Chalmers I: Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting. Lancet. 2010, 376: 20-21. 10.1016/S0140-6736(10)61045-8.CrossRefPubMed
10.
go back to reference Chalmers I: Regulation of therapeutic research is compromising the interests of patients. Int J Clin Pharm Med. 2007, 21: 395-404. 10.2165/00124363-200721060-00004.CrossRef Chalmers I: Regulation of therapeutic research is compromising the interests of patients. Int J Clin Pharm Med. 2007, 21: 395-404. 10.2165/00124363-200721060-00004.CrossRef
11.
go back to reference Richardson WS, Wilson MC, Nishikawa J, Hayward RSA: The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995, 123: A12-PubMed Richardson WS, Wilson MC, Nishikawa J, Hayward RSA: The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995, 123: A12-PubMed
12.
go back to reference Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG: Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008, 337: a2299-10.1136/bmj.a2299.CrossRefPubMedPubMedCentral Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG: Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008, 337: a2299-10.1136/bmj.a2299.CrossRefPubMedPubMedCentral
13.
go back to reference Chuang-Stein C, Anderson K, Gallo P, Collins S: Sample size re-estimation: a review and recommendations. Drug Inform J. 2006, 40: 475-484. Chuang-Stein C, Anderson K, Gallo P, Collins S: Sample size re-estimation: a review and recommendations. Drug Inform J. 2006, 40: 475-484.
14.
go back to reference Schulz KF, Grimes DA: Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005, 365: 1348-1353. 10.1016/S0140-6736(05)61034-3.CrossRefPubMed Schulz KF, Grimes DA: Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005, 365: 1348-1353. 10.1016/S0140-6736(05)61034-3.CrossRefPubMed
15.
go back to reference Djulbegovic B, Kumar A, Magazin A, Schroen A, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ: Optimism bias leads to inconclusive results– an empirical study. J Clin Epidemiol. 2011, 64: 583-593. 10.1016/j.jclinepi.2010.09.007.CrossRefPubMed Djulbegovic B, Kumar A, Magazin A, Schroen A, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ: Optimism bias leads to inconclusive results– an empirical study. J Clin Epidemiol. 2011, 64: 583-593. 10.1016/j.jclinepi.2010.09.007.CrossRefPubMed
16.
go back to reference Rosenberg MJ: The Agile Approach to Adaptive Research. 2010, John Wiley & SonsCrossRef Rosenberg MJ: The Agile Approach to Adaptive Research. 2010, John Wiley & SonsCrossRef
17.
go back to reference Emanuel EJ, Wendler D, Grady C: What makes clinical research ethical?. JAMA. 2000, 283: 2701-2711. 10.1001/jama.283.20.2701.CrossRefPubMed Emanuel EJ, Wendler D, Grady C: What makes clinical research ethical?. JAMA. 2000, 283: 2701-2711. 10.1001/jama.283.20.2701.CrossRefPubMed
18.
go back to reference Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells DW, Ioannidis JPA, Oliver S: Research: increasing value, reducing waste. 1. How to increase value and reduce waste when research priorities are set. Lancet. 2014, 383: 156-165. 10.1016/S0140-6736(13)62229-1.CrossRefPubMed Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells DW, Ioannidis JPA, Oliver S: Research: increasing value, reducing waste. 1. How to increase value and reduce waste when research priorities are set. Lancet. 2014, 383: 156-165. 10.1016/S0140-6736(13)62229-1.CrossRefPubMed
19.
go back to reference Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, Tibshirani R: Research: increasing value, reducing waste. 2. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014, 383: 166-175. 10.1016/S0140-6736(13)62227-8.CrossRefPubMedPubMedCentral Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, Tibshirani R: Research: increasing value, reducing waste. 2. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014, 383: 166-175. 10.1016/S0140-6736(13)62227-8.CrossRefPubMedPubMedCentral
20.
go back to reference Schulz KF, Altman DG, Moher D, for the CONSORT Group: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c332-10.1136/bmj.c332.CrossRefPubMedPubMedCentral Schulz KF, Altman DG, Moher D, for the CONSORT Group: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c332-10.1136/bmj.c332.CrossRefPubMedPubMedCentral
Metadata
Title
Five questions that need answering when considering the design of clinical trials
Authors
Timothy Clark
Hugh Davies
Ulrich Mansmann
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Trials / Issue 1/2014
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-15-286

Other articles of this Issue 1/2014

Trials 1/2014 Go to the issue